Immucell Corp
ICCC- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0000811641
No open-market purchases or sales by Immucell Corp insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $13.4M in total; no superinvestor holds it.
Q2 2024 vs. Q1 2024
How the institutions holding Immucell Corp changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Q2 2024 | Change |
|---|---|---|---|
| Holders | 25 | 28 | +3 |
| Shares | 1.02M | 1.15M | +130.7K (+12.8%) |
| Value | $5.39M | $5.56M | +$162.8K (+3.0%) |
New holders (3)
Institutions that held Immucell Corp at the end of Q2 2024 but not at the end of Q1 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Citadel Advisors LLC | 23,746 | $115.2K | 0.00% |
| Jones Financial Companies LLLP | 19 | $92 | 0.00% |
| Innealta Capital, LLC | 1 | $5 | 0.00% |
Sold out (0)
Institutions that held Immucell Corp at the end of Q1 2024 and filed for Q2 2024 without it.
None.